Feb. 13, 2026
AnaptysBio Insider Sells $540,000 in Stock
Eric Loumeau, an insider at the biotech company, reduced his stake by 43.79%.
Feb. 12, 2026
Neurocrine Biosciences Stock Drops 9.3% After Analyst Downgrade
Needham & Company lowered its price target on the biopharmaceutical company's stock.
Feb. 11, 2026
Neurocrine Reports Q4 Earnings
Biopharmaceutical company posts revenue of $805.5 million, beating Wall Street expectations
Feb. 10, 2026
Brokerages Set Hudson Pacific Properties Price Target at $15.62
Analysts have a 'Hold' rating on the real estate investment trust's stock.
Feb. 10, 2026
ACADIA Pharmaceuticals EVP Sells 6,950 Shares
Insider transaction represents a 47.74% decrease in their position
